Down-regulation of PADI2 Prevents Proliferation and Epithelial-mesenchymal Transition in Ovarian Cancer Through Inhibiting JAK2/STAT3 Pathway in Vitro and in Vivo, Alone or in Combination with Olaparib

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2020 Sep 21

PMID 32951601

Citations 14

Authors

Lidong Liu

Zhiwei Zhang

Guoxiang Zhang

Ting Wang

Yingchun Ma

Wei Guo

Affiliations

Soon will be listed here.

Abstract

Background: Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biological role of PADI2 in ovarian cancer (OC) and the relative mechanism.

Methods: Gene Expression Profiling Interactive Analysis (GEPIA) ( https://gepia.pku.cn/ ) and ONCOMINE ( https://www.oncomine.org/ ) were used to analyze PADI2 Gene Expression data. The survival curve for the PADI2 gene was generated by using the online Kaplan-Meier mapping site ( https://www.kmplot.com/ ). We conducted MTT assay, cloning formation assay and EdU cell proliferation assay to detect the cell activity of PADI2 knockdown A2780 and SKOV3 ovarian cancer cells treated with Olaparib. Cell migration and invasion were observed by would healing and transwell assay. The pathway changes after the treatment of PADI2 were detected by transcriptome sequencing and western blot. The role of PADI2 combined with Olaparib treatment in vivo was studied in nude mouse model bearing ovarian cancer tumor.

Results: We investigated the role of PADI2 on EOC in vitro and in vivo. PADI2 was upregulated in ovarian cancer samples and high PADI2 expression was correlated with poor outcome. Downregulating PADI2 suppressed colony formation, proliferation, migration and invasion of A2780 and SKOV3 cells. Furthermore, downregulating PADI2 and Olaparib combination treatment attenuated the viability, migration and invasion of A2780 and SKOV3 cells. We identified differentially expressed genes in A2780-shPADI2 and SKOV3-shPADI2 cell by transcriptome sequencing analysis and verified that downregulating PADI2 and Olaparib combination treatment suppresses EMT and JAK2/STAT3 signaling pathway in A2780 and SKOV3 cells in vitro and in vivo.

Conclusions: Downregulation of PADI2 and Olaparib combination treatment attenuated the proliferation, migration and invasion of A2780 and SKOV3 cells by inhibiting the EMT through JAK2/STAT3 signaling pathway.

Citing Articles

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway.

Gai M, Zhao L, Li H, Jin G, Li W, Wang F Cancer Biol Ther. 2024; 25(1):2432117.

PMID: 39588922 PMC: 11601053. DOI: 10.1080/15384047.2024.2432117.

Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.

Hung S, Yu C, Lin H, Chiou W, Lee M, Lin R Clin Exp Metastasis. 2024; 41(6):925-935.

PMID: 39215870 DOI: 10.1007/s10585-024-10310-5.

Differential Responses to Aging Among the Transcriptome and Proteome of Mesenchymal Progenitor Populations.

Feehan J, Tripodi N, Kondrikov D, Wijeratne T, Gimble J, Hill W J Gerontol A Biol Sci Med Sci. 2024; 79(9).

PMID: 38837176 PMC: 11369222. DOI: 10.1093/gerona/glae147.

Differential responses to aging amongst the transcriptome and proteome of mesenchymal progenitor populations.

Duque G, Feehan J, Tripodi N, Kondrikov D, Wijeratne T, Gimble J Res Sq. 2024; .

PMID: 38168272 PMC: 10760299. DOI: 10.21203/rs.3.rs-3755129/v1.

Cell Membrane Sialome: Sialic Acids as Therapeutic Targets and Regulators of Drug Resistance in Human Cancer Management.

Jastrzab P, Narejko K, Car H, Wielgat P Cancers (Basel). 2023; 15(20).

PMID: 37894470 PMC: 10604966. DOI: 10.3390/cancers15205103.

References

McElwee J, Mohanan S, Horibata S, Sams K, Anguish L, McLean D . PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia. Cancer Res. 2014; 74(21):6306-17. DOI: 10.1158/0008-5472.CAN-14-0749. View

Tanday S . Targeting PADI2 could stop the progression of myeloma. Lancet Oncol. 2016; 17(8):e325. DOI: 10.1016/S1470-2045(16)30314-X. View

Audeh M, Carmichael J, Penson R, Friedlander M, Powell B, Bell-McGuinn K . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):245-51. DOI: 10.1016/S0140-6736(10)60893-8. View

Guo W, Zheng Y, Xu B, Ma F, Li C, Zhang X . Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. Onco Targets Ther. 2017; 10:1475-1485. PMC: 5352236. DOI: 10.2147/OTT.S92389. View

Asad M, Wajid S, Katare D, Mani R, Jain S . Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications. Curr Cancer Drug Targets. 2019; 19(11):919-929. DOI: 10.2174/1871525717666190717162646. View

Wang H, Xu B, Zhang X, Zheng Y, Zhao Y, Chang X . PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling. Cancer Cell Int. 2016; 16:61. PMC: 4966586. DOI: 10.1186/s12935-016-0335-0. View

Chuang H, Kapuriya N, Kulp S, Chen C, Shapiro C . Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat. 2012; 134(2):649-59. PMC: 4297209. DOI: 10.1007/s10549-012-2106-5. View

Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E . Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. J Natl Cancer Inst. 2016; 108(11). DOI: 10.1093/jnci/djw148. View

Mohanan S, Horibata S, Anguish L, Mukai C, Sams K, McElwee J . PAD2 overexpression in transgenic mice augments malignancy and tumor-associated inflammation in chemically initiated skin tumors. Cell Tissue Res. 2017; 370(2):275-283. DOI: 10.1007/s00441-017-2669-x. View

10.

Gao B, Rong C, Xu H, Sun T, Hou J, Xu Y . Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer. Pathol Oncol Res. 2019; 26(2):1279-1285. DOI: 10.1007/s12253-019-00687-0. View

11.

Tu R, Grover H, Kotra L . Peptidyl Arginine Deiminases and Neurodegenerative Diseases. Curr Med Chem. 2015; 23(2):104-14. DOI: 10.2174/0929867323666151118120710. View

12.

Faraoni I, Graziani G . Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel). 2018; 10(12). PMC: 6316750. DOI: 10.3390/cancers10120487. View

13.

Cherrington B, Zhang X, McElwee J, Morency E, Anguish L, Coonrod S . Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One. 2012; 7(7):e41242. PMC: 3404060. DOI: 10.1371/journal.pone.0041242. View

14.

Wesche J, Kuhn S, Kessler B, Salton M, Wolf A . Protein arginine methylation: a prominent modification and its demethylation. Cell Mol Life Sci. 2017; 74(18):3305-3315. PMC: 11107486. DOI: 10.1007/s00018-017-2515-z. View

15.

Liu Y, Fan J, Yang H, Xu E, Wei W, Zhang Y . Detection of PARP-1 activity based on hyperbranched-poly (ADP-ribose) polymers responsive current in artificial nanochannels. Biosens Bioelectron. 2018; 113:136-141. DOI: 10.1016/j.bios.2018.05.005. View

16.

Steffen J, Tholey R, Langelier M, Planck J, Schiewer M, Lal S . Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res. 2013; 74(1):31-7. PMC: 3903668. DOI: 10.1158/0008-5472.CAN-13-1701. View

17.

Liu L, Pang Y, Zhao X, Li R, Jin C, Xue J . Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells. Arch Gynecol Obstet. 2019; 299(6):1627-1639. DOI: 10.1007/s00404-019-05058-3. View

18.

Schacke M, Kumar J, Colwell N, Hermanson K, Folle G, Nechaev S . PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells. Int J Mol Sci. 2019; 20(3). PMC: 6387051. DOI: 10.3390/ijms20030518. View

19.

Su J, Morgani S, David C, Wang Q, Er E, Huang Y . TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020; 577(7791):566-571. PMC: 7450666. DOI: 10.1038/s41586-019-1897-5. View

20.

Jiang L, Zhao X, Mao Y, Wang J, Zheng H, You Q . Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. J Exp Clin Cancer Res. 2019; 38(1):465. PMC: 6852742. DOI: 10.1186/s13046-019-1428-0. View